ID: ALA4799695

Max Phase: Preclinical

Molecular Formula: C76H121N21O19

Molecular Weight: 1632.93

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)O

Standard InChI:  InChI=1S/C76H121N21O19/c1-8-42(6)61(71(112)94-56(74(115)116)36-41(4)5)95-68(109)54(38-45-22-26-47(99)27-23-45)93-70(111)58-19-14-34-97(58)73(114)51(17-12-32-85-76(82)83)88-63(104)48(16-11-31-84-75(80)81)87-69(110)57-18-13-33-96(57)72(113)50(15-9-10-30-77)89-67(108)55(39-59(79)100)92-64(105)49(28-29-60(101)102)86-66(107)53(37-44-20-24-46(98)25-21-44)91-65(106)52(35-40(2)3)90-62(103)43(7)78/h20-27,40-43,48-58,61,98-99H,8-19,28-39,77-78H2,1-7H3,(H2,79,100)(H,86,107)(H,87,110)(H,88,104)(H,89,108)(H,90,103)(H,91,106)(H,92,105)(H,93,111)(H,94,112)(H,95,109)(H,101,102)(H,115,116)(H4,80,81,84)(H4,82,83,85)/t42-,43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1

Standard InChI Key:  LJDKIRQGXSOPEQ-JYDDPDNISA-N

Associated Targets(Human)

Neurotensin receptor 1 1525 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Neurotensin receptor 2 296 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1632.93Molecular Weight (Monoisotopic): 1631.9148AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P.  (2021)  Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic.,  64  (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726]

Source